MEDIA RELEASE

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

Torrent Pharma announces Q3 FY20 results, EBITDA grows by 6%
January 27th, 2020

Torrent Pharmaceuticals Ltd ('Torrent'), is ranked 8th in Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), and Vitamins Minerals Nutritional (VMN). It is specialty-focused company with 73% of its revenue from chronic & sub-chronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines.

Torrent has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 700 scientists.

Torrent continues to be focused on specialty driven business, productivity improvement, brand building, maintaining high quality manufacturing practices and investments into R&D for a robust future pipeline.

Key highlights: Q3 FY20 consolidated financials

- Revenues at Rs. 1,966 crores (down by 4%). Adjusted for one-time settlement income in Q3 FY19, revenues are down by 1%.
  - India business at Rs. 871 crores (up by 5% YoY). Adjusted for one off's, the growth is 8.5%. One off's pertain to integration of Torrent and Unichem stockist in Q3 FY 19 and the base impact of products discontinued in the last year.
  - US revenues at Rs. 381 crores (down by 22% YoY). 3 ANDAs were filed during the quarter. As on December 31st 2019, 45 ANDAs are pending approval and 6 tentative approvals have been received.
  - Germany revenues at Rs. 219 crores (down by 18% YoY).
  - Brazil revenues at Rs. 189 crores (up by 12% YoY). Constant currency growth is 23%.
- Gross margins at 72.4%.
- EBITDA at Rs. 591 crores (EBITDA margin of 30%), up by 6% (YoY). Adjusted for one-time impact of patent related settlement and litigation cost in previous year, EBITDA growth is 13%.
- Net profit at Rs. 251 crores as against Rs. 246 crores in Q3 FY19, up by 2% (YoY). Adjusted for one-time impact of patent related settlement and litigation cost in previous year, Net profit is up by 17%.
- R&D spend at Rs. 110 crores against Rs. 135 crores in Q3 FY19.

Key highlights: 9 months FY20 consolidated financials

- Revenues at Rs 5,993 crores (YoY growth of 3%).
- Gross margins at 72.7%
- EBITDA at Rs. 1,723 crores (EBITDA margin of 29%), up by 12% (YoY).
- Net profit at Rs. 711 crores as against Rs. 588 crores in YTD FY19, up by 21% (YoY).
- R&D spend at Rs. 376 crores against Rs. 400 crores in YTD FY19.

About Torrent Pharma
Torrent Pharma, with annual revenues of more than Rs. 7,600 crores is the flagship Company of the Torrent Group. Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.